Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Cancer Res. 2009 Nov 10;69(23):8910–8917. doi: 10.1158/0008-5472.CAN-09-1543

Figure 6.

Figure 6

GSK-3β inhibitor SB216763 compromises the ability of tangeretin-cisplatin combination to induce apoptosis. SB216763 was applied 1 hour prior to treatment combination. A, PARP cleavage was determined by Western blot analysis. B, Apoptosis of drug treated cells was quantitatively examined using Cell Death ELISA. Symbol ** shows significant difference (p<0.001) of the corresponding combination group without SB216763 by Tukey-Kramer Multiple Comparisons Test; n=3.